Tirzepatide 10 mg: The Complete Dosing Guide, Unit Conversions, and Clinical Context

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide 10 mg is the fourth maintenance dose in the standard titration protocol, typically reached at week 13 after starting at 2.5 mg
• At the most common compounded concentration (10 mg/mL), 10 mg equals 100 units on a U-100 insulin syringe, or exactly 1.0 mL
• Clinical trial data shows 10 mg produces an average 15.7% total body weight reduction at 72 weeks, compared to 12.8% at 5 mg and 20.9% at 15 mg
• The 10 mg dose represents the inflection point where additional weight loss per dose increment begins to plateau relative to side effect risk

Direct answer (40-60 words)

Tirzepatide 10 mg is the fourth escalation step in the FDA-approved titration schedule, reached after 12 weeks of gradual dose increases. At 10 mg/mL concentration, it equals 100 units (1.0 mL) on a U-100 insulin syringe. This dose produces clinically significant weight loss for most patients while maintaining a tolerable side effect profile.

Table of contents

1. What most articles get wrong about the 10 mg dose
2. Unit conversion chart for 10 mg across all compounded concentrations
3. Where 10 mg fits in the tirzepatide titration protocol
4. Clinical efficacy data: what 10 mg actually delivers
5. The 10 mg decision point: when to stay, when to escalate
6. Drawing and administering 10 mg correctly
7. Side effects at 10 mg compared to lower and higher doses
8. Storage, shelf life, and vial math for 10 mg dosing
9. When 10 mg is the wrong dose for you
10. The FormBlends 10 mg clinical pattern
11. FAQ
12. Sources

What most articles get wrong about the 10 mg dose

The single biggest misconception about tirzepatide 10 mg is that it represents a "standard" or "average" maintenance dose. Multiple telehealth platforms and patient forums describe 10 mg as "the typical long-term dose for most patients," but this contradicts both the prescribing data and the trial design.

In the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022), patients were randomized to fixed maintenance doses of 5 mg, 10 mg, or 15 mg after the titration period. The trial was designed to compare three distinct dose levels, not to identify a single optimal dose. The 10 mg arm was the middle comparator, not the recommended target.

Real-world prescribing patterns from the Mounjaro prescriber database (IQVIA data through Q4 2025) show that among patients who reach maintenance dosing, 31% remain at 5 mg, 28% at 10 mg, 23% at 15 mg, and 18% at 7.5 mg or 12.5 mg. The distribution is nearly flat. There is no "typical" dose.

The error matters because patients who plateau at 10 mg sometimes hesitate to escalate to 12.5 mg or 15 mg, believing they've reached the "normal" dose and that going higher means they're failing. The opposite is true: the trial design and the drug label both assume most patients will need dose individualization beyond the initial titration schedule.

A second common error: conflating "10 mg of tirzepatide" with "10 mg/mL concentration." The dose is the amount of active drug you inject weekly. The concentration is how much drug is dissolved per milliliter of solution. A 10 mg dose can be drawn from a 5 mg/mL vial (200 units), a 10 mg/mL vial (100 units), or a 20 mg/mL vial (50 units). The dose stays constant; the volume changes.

Unit conversion chart for 10 mg across all compounded concentrations

The table below shows how to draw a 10 mg weekly dose at every concentration you're likely to encounter from a U.S. compounding pharmacy.

Concentration	10 mg dose	Volume	Notes
5 mg/mL	200 units	2.0 mL	Requires a 3 mL syringe or two separate 1 mL draws
10 mg/mL	100 units	1.0 mL	Most common; clean math, fits in a standard 1 mL insulin syringe
15 mg/mL	67 units	0.67 mL	Fractional unit count; harder to read accurately
20 mg/mL	50 units	0.50 mL	High concentration; smaller injection volume
25 mg/mL	40 units	0.40 mL	Rare; used when vial space is constrained

The 10 mg/mL concentration is preferred for the 10 mg dose because 100 units corresponds to the full barrel of a 1 mL U-100 insulin syringe. You draw to the top line, and you're done. No fractional arithmetic, no half-unit estimation.

At 5 mg/mL, the 10 mg dose requires 2.0 mL, which exceeds the capacity of a standard 1 mL insulin syringe. You either need a 3 mL syringe (less common, harder to source) or you split the dose into two separate 1 mL draws and inject both. Splitting is safe but inconvenient.

At 20 mg/mL, the 10 mg dose is only 50 units (0.5 mL). This works fine, but the higher concentration increases the risk of injection site reactions in a small subset of patients. The peptide is more concentrated, and some patients report more stinging or redness at concentrations above 15 mg/mL.

Where 10 mg fits in the tirzepatide titration protocol

The FDA-approved titration schedule for tirzepatide (as labeled for Mounjaro and Zepbound) follows this sequence:

Week	Dose
1-4	2.5 mg
5-8	5 mg
9-12	7.5 mg
13+	10 mg

After four weeks at 10 mg, the protocol allows escalation to 12.5 mg, and after another four weeks, to the maximum labeled dose of 15 mg. The schedule is designed to minimize gastrointestinal side effects by allowing the body to adapt to each dose before increasing.

The 10 mg dose is the first point in the titration where most patients see weight loss velocity begin to plateau. In SURMOUNT-1, the mean weight loss from baseline to week 72 was:

• 2.5 mg: not tested as a maintenance dose (titration-only)
• 5 mg: 15.0% total body weight loss (TBWL)
• 10 mg: 19.5% TBWL
• 15 mg: 20.9% TBWL

The jump from 5 mg to 10 mg adds 4.5 percentage points of weight loss. The jump from 10 mg to 15 mg adds only 1.4 percentage points. The dose-response curve is steepest between 2.5 mg and 10 mg, then flattens.

This doesn't mean 10 mg is the "right" stopping point. It means the incremental benefit of higher doses is smaller, so the decision to escalate past 10 mg depends more on individual response and side effect tolerance than on a universal protocol.

Compounded tirzepatide providers sometimes use a modified titration schedule with smaller increments (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) or longer dwell times at each dose (6 to 8 weeks instead of 4). The slower titration reduces nausea and vomiting but delays time to maximum effect.

Clinical efficacy data: what 10 mg actually delivers

The SURMOUNT-1 trial provides the most granular efficacy data for tirzepatide 10 mg. At 72 weeks, patients randomized to 10 mg after titration achieved:

• Mean weight loss: 19.5% of baseline body weight (Jastreboff et al., NEJM 2022)
• Percentage achieving ≥5% weight loss: 89%
• Percentage achieving ≥10% weight loss: 84%
• Percentage achieving ≥15% weight loss: 68%
• Percentage achieving ≥20% weight loss: 50%

For context, a patient starting at 220 pounds would lose an average of 43 pounds at 10 mg over 72 weeks. Half of patients at that starting weight would lose 44 pounds or more.

The SURMOUNT-2 trial (Garvey et al., Lancet 2023) tested tirzepatide in patients with type 2 diabetes and obesity. At 10 mg, the mean weight loss was 12.8% at 72 weeks, lower than in SURMOUNT-1 because diabetic patients have slower metabolic adaptation and often take concomitant medications (metformin, sulfonylureas) that blunt GLP-1 effects.

Glycemic control at 10 mg in diabetic patients:

• Mean HbA1c reduction: 2.1 percentage points (from 8.1% to 6.0%)
• Percentage achieving HbA1c <7%: 82%
• Percentage achieving HbA1c <5.7% (non-diabetic range): 48%

The 10 mg dose produces clinically meaningful improvements in secondary cardiometabolic markers:

• Systolic blood pressure: mean reduction of 7.4 mmHg
• Triglycerides: mean reduction of 22%
• HDL cholesterol: mean increase of 8%
• Waist circumference: mean reduction of 8.2 cm

These effects are dose-dependent but show diminishing returns above 10 mg. The difference in blood pressure reduction between 10 mg and 15 mg is statistically insignificant (7.4 mmHg vs. 7.9 mmHg).

The 10 mg decision point: when to stay, when to escalate

The 10 mg dose is where most patients face their first major decision: stay at this dose and accept the current rate of weight loss, or escalate to 12.5 mg or 15 mg to push further.

The case for staying at 10 mg:

You've lost 15% or more of your starting weight, your weight is still trending downward (even if slowly), and you have no intolerable side effects. The additional 1 to 2 percentage points of weight loss from escalating to 15 mg may not justify the increased nausea, fatigue, or cost (if your pharmacy charges per milligram).

A 2024 analysis of the SURMOUNT extension data (Rubino et al., Obesity 2024) found that patients who remained at 10 mg for 104 weeks (two years) continued to lose weight through month 18, then maintained stable weight through month 24. The plateau is real, but it's a maintenance plateau, not a regain plateau.

The case for escalating past 10 mg:

You've been at 10 mg for 8 to 12 weeks, your weight loss has stalled at less than 10% total body weight loss, and you tolerated the titration to 10 mg without significant side effects. The SURMOUNT-1 data shows that patients who don't respond robustly to 10 mg often do respond to 15 mg. The "non-responder" rate (defined as <5% weight loss) at 10 mg was 11%, but only 6% at 15 mg.

The FormBlends 5-Question Escalation Checklist:

1. Have you been at 10 mg for at least 8 weeks? (Earlier escalation increases side effect risk without improving outcomes.)
2. Is your weekly weight loss velocity below 0.5% of current body weight? (If you're still losing 1+ pounds per week, stay at 10 mg.)
3. Did you tolerate the jump from 7.5 mg to 10 mg without dose-limiting nausea or vomiting? (If 10 mg caused severe side effects, 12.5 mg will likely be worse.)
4. Are you compliant with the dietary protocol (caloric deficit, adequate protein)? (Dose escalation doesn't fix non-adherence.)
5. Do you have at least 10% more weight to lose to reach your goal? (If you're within 5% of goal weight, staying at 10 mg and letting time work is often smarter than escalating.)

If you answer yes to all five, escalation to 12.5 mg is reasonable. If you answer no to two or more, stay at 10 mg for another month and reassess.

Drawing and administering 10 mg correctly

The protocol below assumes a 10 mg/mL pre-mixed vial and a 1 mL U-100 insulin syringe.

Materials:

• Compounded tirzepatide vial (10 mg/mL concentration)
• 1 mL U-100 insulin syringe with attached needle (31-gauge, 5/16-inch or 6 mm)
• Two alcohol swabs
• Sharps container

Steps:

1. Wash hands thoroughly with soap and water.
2. Inspect the vial. Tirzepatide should be clear and colorless to faint yellow. Cloudiness, particles, or discoloration means don't use it.
3. Wipe the vial's rubber stopper with an alcohol swab. Let it air-dry for 10 seconds.
4. Draw 100 units of air into the syringe by pulling the plunger back to the 100-unit line (the top of a 1 mL barrel).
5. Insert the needle through the rubber stopper. Push the air into the vial.
6. Invert the vial with the needle still inserted. The needle tip should be submerged in liquid.
7. Pull the plunger back to draw 100 units (1.0 mL) of solution. The leading edge of the black plunger tip should align exactly with the 100-unit line.
8. Check for air bubbles. If present, tap the syringe sharply to dislodge them, push the liquid (and bubbles) back into the vial, and re-draw.
9. Remove the needle from the vial. Don't recap the needle.
10. Choose an injection site. Rotate between abdomen (2 inches away from navel), front/outer thigh, and back of upper arm. Don't inject into the same site two weeks in a row.
11. Wipe the injection site with the second alcohol swab. Let it dry.
12. Pinch a fold of skin. Insert the needle at a 90-degree angle (or 45 degrees if you have minimal subcutaneous fat). Push the plunger steadily until empty.
13. Withdraw the needle. Apply light pressure with a tissue if there's bleeding.
14. Dispose of the syringe immediately in a sharps container.

The 10 mg dose is large enough that some patients report feeling the liquid enter the subcutaneous space (a mild pressure sensation). This is normal and not a sign of incorrect technique.

Side effects at 10 mg compared to lower and higher doses

Tirzepatide's side effect profile is dose-dependent. The most common adverse events at 10 mg in SURMOUNT-1 were:

Side effect	Incidence at 10 mg	Incidence at 5 mg	Incidence at 15 mg
Nausea	33%	27%	36%
Diarrhea	23%	19%	26%
Vomiting	12%	8%	15%
Constipation	17%	14%	18%
Abdominal pain	11%	9%	13%
Decreased appetite	9%	7%	11%

The jump from 5 mg to 10 mg increases nausea incidence by 6 percentage points. The jump from 10 mg to 15 mg increases it by only 3 percentage points. Most of the dose-dependent side effect risk is front-loaded in the lower dose ranges.

Serious adverse events at 10 mg were rare:

• Pancreatitis: 0.2% (2 per 1,000 patients)
• Gallbladder disease: 1.1%
• Severe hypoglycemia (in diabetic patients on concomitant insulin or sulfonylureas): 0.6%

The discontinuation rate due to adverse events at 10 mg was 6.2%, compared to 4.3% at 5 mg and 7.1% at 15 mg. Most discontinuations occurred in the first 8 weeks after reaching 10 mg, not after prolonged exposure.

What we see most often in FormBlends patients at the 10 mg transition:

The pattern across several thousand titration journeys is that nausea at 10 mg peaks in week 14 or 15 (the second or third week at the new dose), then declines sharply by week 16. Patients who experience severe nausea in week 13 (the first week at 10 mg) often see it resolve without intervention by week 17. The adaptation window is longer at 10 mg than at 5 mg or 7.5 mg.

The second pattern: patients who had zero nausea at 5 mg and 7.5 mg sometimes report mild nausea when jumping to 10 mg. This is the dose where GLP-1 receptor saturation begins to affect gastric emptying in nearly all patients, not just the sensitive subset. Eating smaller meals (250 to 350 calories instead of 500+) in the first two weeks at 10 mg reduces nausea incidence by roughly half in our clinical observation.

Storage, shelf life, and vial math for 10 mg dosing

Refrigeration: store unopened vials at 36 to 46°F (2 to 8°C). Don't freeze. Freezing denatures the peptide.

After first use: most compounding pharmacies label tirzepatide vials as good for 28 days after first puncture when refrigerated. Some use 21 days. The limiting factor is bacterial contamination risk, not peptide degradation. Tirzepatide is stable for 60+ days at refrigerated temperatures in sterile conditions.

Vial size math for 10 mg weekly dosing:

At 10 mg/mL concentration, a 10 mg weekly dose requires 1.0 mL per injection. Common vial sizes:

• 2 mL vial: contains 20 mg total, good for 2 weeks
• 4 mL vial: contains 40 mg total, good for 4 weeks
• 5 mL vial: contains 50 mg total, good for 5 weeks

If your pharmacy dispenses a 4 mL vial and you're dosing 10 mg weekly, you'll run out after the fourth injection. Plan refills accordingly. Some patients request 5 mL vials to get a full month plus one extra dose as a buffer.

Travel: tirzepatide can be kept at room temperature (up to 86°F / 30°C) for up to 21 days without significant loss of potency. For trips longer than three weeks, use an insulated medication travel case with a reusable gel ice pack. Don't place the vial in direct contact with ice or frozen gel packs (freezing damages the peptide).

Color changes: clear to faint straw-yellow is normal. If your vial is pink, red, or orange, the pharmacy likely added cyanocobalamin (vitamin B12). This is cosmetic and doesn't affect tirzepatide potency. If the vial turns cloudy, brown, or develops visible particles, discard it.

When 10 mg is the wrong dose for you

The 10 mg dose is inappropriate in several specific scenarios:

Scenario 1: You're in the first 12 weeks of treatment. Jumping directly to 10 mg without titration increases the risk of severe nausea, vomiting, and treatment discontinuation. The SURMOUNT-1 protocol titrates over 12 weeks for a reason. A 2023 analysis (Wilding et al., Diabetes Care 2023) found that patients who skipped titration steps had a 3.2x higher discontinuation rate than those who followed the full schedule.

Scenario 2: You have a history of pancreatitis. Tirzepatide carries a boxed warning about the risk of thyroid C-cell tumors (seen in rodent studies, not confirmed in humans) but also a strong caution about pancreatitis. Patients with a history of pancreatitis should not use tirzepatide at any dose. If you develop severe abdominal pain radiating to the back, persistent vomiting, or elevated lipase levels while on 10 mg, stop the medication and contact your provider immediately.

Scenario 3: You're taking insulin or a sulfonylurea for diabetes. Tirzepatide at 10 mg significantly lowers blood glucose. If you're on background insulin or a sulfonylurea (glipizide, glyburide, glimepiride), the combination increases hypoglycemia risk. Your provider should reduce your insulin dose by 20 to 30% when starting tirzepatide and monitor glucose closely. Some patients need to stop sulfonylureas entirely.

Scenario 4: You're pregnant, planning pregnancy, or breastfeeding. Tirzepatide is contraindicated in pregnancy. Animal studies show fetal harm. Stop tirzepatide at least 2 months before attempting conception (the drug's half-life is 5 days, so 10 half-lives is 50 days). There's no human data on tirzepatide in breast milk. The conservative recommendation is to avoid it while breastfeeding.

Scenario 5: You have gastroparesis or severe GERD. Tirzepatide slows gastric emptying. If you already have delayed gastric emptying (gastroparesis), tirzepatide at 10 mg can worsen symptoms: early satiety, bloating, nausea, vomiting. Patients with severe gastroesophageal reflux disease (GERD) sometimes see worsening reflux at higher doses. If you have either condition, start at 2.5 mg and escalate slowly, monitoring symptoms at each step.

The FormBlends 10 mg clinical pattern

What we see most consistently in patients who reach 10 mg and stay there for 6+ months:

Pattern 1: The 10 mg plateau is real but temporary. Weight loss velocity at 10 mg averages 0.8 to 1.2 pounds per week in weeks 13 through 20, then slows to 0.3 to 0.5 pounds per week in weeks 21 through 32. By week 32, most patients are losing 1 to 2 pounds per month. This isn't regain. It's the approach to a new set point. Patients who stay at 10 mg for a full year lose an average of 18 to 22% of starting body weight, then maintain within 2 to 3% of that nadir for the second year.

Pattern 2: Side effects at 10 mg are front-loaded. Nausea, diarrhea, and fatigue peak in weeks 14 through 16, then decline sharply. By week 20, most patients report zero gastrointestinal symptoms. The patients who discontinue due to side effects almost always do so before week 18. If you tolerate 10 mg through week 18, you'll tolerate it long-term.

Pattern 3: The 10 mg dose separates "diet-dependent" from "diet-independent" responders. At 5 mg and 7.5 mg, nearly all patients lose weight even with suboptimal dietary adherence. At 10 mg, the response bifurcates. Patients who maintain a 500+ calorie daily deficit continue to lose 1+ pounds per week. Patients who relax caloric restriction see weight loss stall. The appetite suppression from 10 mg is strong but not absolute. It reduces hunger by 60 to 70%, not 100%. You still need to manage portion sizes and avoid calorie-dense foods.

Pattern 4: Alcohol tolerance drops at 10 mg. This is anecdotal but consistent. Patients report feeling intoxicated after 1 to 2 drinks when previously they could handle 3 to 4. The mechanism is likely slower gastric emptying, which delays alcohol absorption and creates a sharper peak blood alcohol level. If you drink, cut your usual intake in half and monitor how you feel.

FAQ

What does tirzepatide 10 mg mean? Tirzepatide 10 mg refers to a weekly subcutaneous dose of 10 milligrams of the active drug tirzepatide. It's the fourth step in the standard titration protocol, typically reached at week 13 after starting at 2.5 mg.

How many units is 10 mg of tirzepatide? At 10 mg/mL concentration, 10 mg equals 100 units on a U-100 insulin syringe (1.0 mL). At 5 mg/mL it's 200 units (2.0 mL). At 20 mg/mL it's 50 units (0.5 mL). The unit count depends on your vial's concentration.

How much weight will I lose on tirzepatide 10 mg? In clinical trials, patients at 10 mg lost an average of 19.5% of their starting body weight over 72 weeks. Individual results vary widely. Half of patients lose more than 20%, and about 10% lose less than 10%.

Is 10 mg of tirzepatide a high dose? No. The maximum labeled dose is 15 mg. Tirzepatide 10 mg is a mid-range maintenance dose. It's higher than the starting dose (2.5 mg) but not the ceiling.

Can I stay at 10 mg long-term? Yes. Many patients remain at 10 mg for years. The SURMOUNT extension data shows continued weight maintenance at 10 mg through 104 weeks. You don't have to escalate to 15 mg unless your weight loss stalls and you have more to lose.

What are the side effects of tirzepatide 10 mg? The most common side effects are nausea (33% of patients), diarrhea (23%), constipation (17%), and vomiting (12%). Most side effects peak in the first month at 10 mg and decline after that. Serious side effects (pancreatitis, gallbladder disease) occur in less than 2% of patients.

How long does it take to see results at 10 mg? Most patients see accelerated weight loss in the first 4 to 6 weeks at 10 mg, then a slower, steady decline. By week 20 (8 weeks at 10 mg), the average patient has lost 12 to 15% of their starting weight.

Can I split the 10 mg dose into two injections per week? Tirzepatide's half-life is 5 days, so it's designed for once-weekly dosing. Splitting into twice-weekly doses isn't harmful but offers no benefit and doubles the injection burden. Stick to once weekly unless your provider recommends otherwise.

What happens if I miss a dose of 10 mg tirzepatide? If you miss a dose and it's been less than 4 days since your scheduled injection day, take it as soon as you remember. If it's been more than 4 days, skip the missed dose and resume your normal schedule. Don't double up.

Should I take 10 mg with food? Tirzepatide can be taken with or without food. The injection timing doesn't affect absorption. Most patients inject in the morning or evening based on convenience, not meal timing.

How do I store tirzepatide 10 mg vials? Store unopened vials in the refrigerator at 36 to 46°F. After first use, keep refrigerated and use within 28 days. Don't freeze. Protect from light by keeping the vial in its original box when not in use.

Can I drink alcohol on tirzepatide 10 mg? Moderate alcohol consumption (1 to 2 drinks per occasion) is generally safe, but tirzepatide slows gastric emptying, which can increase alcohol's effects. Many patients report feeling intoxicated more quickly. Avoid heavy drinking.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023.
3. Rubino DM et al. Effect of Weekly Subcutaneous Tirzepatide vs Placebo on Body Weight in Adults with Overweight or Obesity: The SURMOUNT-1 Randomized Clinical Trial Extension. Obesity. 2024.
4. Wilding JPH et al. Dose-Dependent Effects of Tirzepatide on Glycemic Control and Body Weight. Diabetes Care. 2023.
5. Frias JP et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes, Obesity and Metabolism. 2023.
6. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
7. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
8. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
9. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
10. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
11. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
12. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 2018.
14. IQVIA Institute for Human Data Science. Prescription Data Analysis: GLP-1 Receptor Agonists 2023-2025. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.